TBX2 and melanoma: This study shows for the first time that niclosamide, piroctone olamine and pyrvinium pamoate can negatively regulate the oncogenic TBX2 and TBX3, and it also broadens the anti‐cancer activity of these drugs to include efficacy against melanoma and rhabdomyosarcoma.